The recent rise of specialty pharma is attributed to its flexible, versatile, and open business model while the traditional big pharma is facing a challenging time with patent cliff, generic threat, and low research and development (R&D) productivity. These multinational pharmaceuticalcompanies,facinga,havebeensystematicallyexternalizingR&Dand some even establish their own corporate venture ca…